Hair loss drug showdown: which works better?

NCT ID NCT07190534

Not yet recruiting Disease control Sponsor: Erasmus Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two medicines, hydroxychloroquine and methotrexate, to see which works better for frontal fibrosing alopecia, a type of scarring hair loss that mainly affects women. About 50 adults who choose to start one of these treatments will be followed for up to 48 weeks. The goal is to measure how well each medicine controls disease activity and improves quality of life, helping doctors make better treatment recommendations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRONTAL FIBROSING ALOPECIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia disorder of pilosebaceous unit frontal fibrosing alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CICATRICIAL ALOPECIA FRONTAL FIBROSING ALOPECIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Erasmus MC University Medical Center

Rotterdam, South Holland, 3015GD, Netherlands

Contact Phone: •••-•••-•••• Email: •••••@•••••